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Abstract Content: Acute TTP is a life-threatening medical emergency and plasma exchange is the only treatment shown
to significantly impact acute mortality (Rock et al, N Engl J Med 1991). Diagnosis can be challenging and therein
arrangements for PEX must be made, with most centres in the United Kingdom (UK) having to co-ordinate transfer to a
tertiary site. To understand issues affecting practice the trainee research network HaemSTAR conducted a retrospective
nationwide review of patients presenting to UK hospitals with TTP against British Society of Haematology clinical
guidelines (Scully et al, B J Haem 2012). Analysis was conducted on the time from first full blood count to initiation of
treatment and impact on patient outcomes.
Adults  ≥18  years  presenting  to  hospital  between  1st  June  2014  and  1st  June  2019  with  first  episode  acute  TTP  and
ADAMTS13  level  <10%  were  identified  by  local  clinicians.  Anonymized  data  of  baseline  characteristics  and  treatment
times  was  submitted  via  an  online  secure  server.  Time  to  PEX  was  defined  as  time  from  receipt  of  the  first  full  blood
count  sample  in  the  laboratory  to  time  of  plasma  release  for  PEX  from  blood  bank.  Where  patients  were  transferred
between sites data was linked retrospectively.
Data on 148 patients treated at  80 UK hospitals was used for  analysis (Table 1).  The overall  median time to PEX from
initial  presentation  was 15 hours  (95% CI  11.3-18.7).    Availability  of  on-site  PEX was associated  with  earlier  treatment
initiation with  median time to  PEX for  those treated on site  10 hrs  (95% CI  7.7-12.3)  vs.  21 hrs  (95% CI  16.8-25.2)  for
patients transferred. A blood film comment of red cell fragments significantly impacted time to treatment: in 24 cases with
no  fragments  documented  median  time  to  PEX  was  110  hrs  (95%  CI  39-181)  vs.  10  hrs  (95%  CI  8.5-11.5)  in  cases
where fragments were reported.
On  univariate  and  multivariate  analysis  age  <60  years,  haemoglobin  (Hb)  <100  g/L,  presence  of  fragments,  PEX
available on-site and admissions occurring after May 2017 were significant predictors for PEX initiation within 8 hrs.
This  is  the  first  multi-centre  record  of  time  to  treatment  from  initial  presentation  of  acute  TTP.  Results  comply  with
guidance  for  rapid  initiation  of  PEX with  61% patients  commencing  within  24  hrs  of  presentation  and,  from June  2017,
34% of patients initiating PEX within 8 hrs. The recent increase in early PEX initiation correlates with initiatives to improve
treatment pathway efficiency following diagnosis of TTP. Early use of steroids and rituximab correlated with earlier use of
PEX  indicating  where  timely  diagnosis  was  made  there  was  good  compliance  with  guidelines.  Inappropriate  use  of
platelets appeared attributable to misdiagnosis.
Older patients, those with higher platelet counts and haemoglobin and absence of red cell fragments on film report were
more likely to experience prolonged time to initiation of PEX. This does not appear related to PEX access, but most likely
the difficulty of making TTP diagnosis in this cohort. That 22% of patients initiated PEX over 48 hrs from admission
indicates the issue is relatively common and with several deaths occurring in this group we suggest initiatives to increase
early diagnosis should be prioritised. 
Abstract Table: Table 1: Numbers of patients meeting key performance indicators in the treatment of acute thrombotic
thrombocytopenic purpura.
  No. of patients (%)
Total included in analysis 148  
Received PEX (total) 142 96
Received PEX (at site of presentation) 67 47
Received PEX (after hospital transfer) 75 53
Received PEX within 8 hours of first full blood count 37 25
Received PEX within 24 hours of first full blood count 91 61
Died before receiving PEX 6 4
Received Steroids within 24 hours of first full blood count 96 65
Received  Rituximab within  48  hours  of  first  full  blood  count  (of  the  128  presenting  with  cardiac  or
central nervous system symptoms)
98 77
Received platelet transfusion in the absence of major bleeding 12 8
Died within 30 days of presentation 19 13
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